Free Trial
→ URGENT: Someone's Moving Gold Out of London... (From Golden Portfolio) (Ad) Buy IMVT Stock  Free IMVT Stock Alerts

Immunovant (IMVT) Financials

Immunovant logo
$15.07 +0.62 (+4.29%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Immunovant

Annual Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -29 -66 -107 -157 -211 -259
Consolidated Net Income / (Loss)		 -29 -66 -107 -157 -211 -259
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -157 -211 -259
Total Pre-Tax Income 		-29 -66 -108 -157 -211 -259
Total Operating Income		 -28 -66 -108 -156 -218 -283
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 28 66 108 156 218 283
Selling, General & Admin Expense		 2.69 18 40 54 48 57
Research & Development Expense		 26 48 69 102 170 225
Total Other Income / (Expense), net		 -0.16 -0.21 0.33 -0.78 7.33 24
Interest Expense		 0.00 0.63 - 0.00 -7.58 -25
Other Income / (Expense), net		 -0.16 0.41 0.33 -0.78 -0.25 -1.01
Income Tax Expense		 0.02 0.10 -0.36 -0.08 0.01 0.57
Basic Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.43) ($1.71) ($1.88)
Weighted Average Basic Shares Outstanding		 22.17M 43.20M 87.76M 109.68M 123.08M 138.10M
Diluted Earnings per Share		 ($1.29) ($1.54) ($1.22) ($1.43) ($1.71) ($1.88)
Weighted Average Diluted Shares Outstanding		 22.17M 43.20M 87.76M 109.68M 123.08M 138.10M
Weighted Average Basic & Diluted Shares Outstanding		 22.17M 43.20M 87.76M 116.51M 130.41M 146.05M

Quarterly Income Statements for Immunovant

This table shows Immunovant's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Income / (Loss) Attributable to Common Shareholders		 -40 -48 -63 -59 -74 -59 -51 -75 -87 -109 -111
Consolidated Net Income / (Loss)		 -40 -48 -63 -59 -74 -59 -51 -75 -87 -109 -111
Net Income / (Loss) Continuing Operations		 -40 -48 -63 -59 -74 -59 -51 -75 -87 -109 -111
Total Pre-Tax Income 		-40 -48 -63 -60 -74 -58 -52 -75 -87 -109 -111
Total Operating Income		 -40 -50 -64 -64 -78 -62 -62 -81 -94 -116 -114
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 40 50 64 64 78 62 62 81 94 116 114
Selling, General & Admin Expense		 12 12 12 12 15 14 13 15 19 18 20
Research & Development Expense		 28 38 52 52 63 48 48 66 75 97 95
Total Other Income / (Expense), net		 0.35 1.95 1.19 3.84 4.53 3.59 10 5.79 7.21 6.70 3.33
Interest & Investment Income		 - - - - 4.07 3.57 8.93 - 7.18 6.07 4.59
Other Income / (Expense), net		 0.35 0.79 -1.76 0.36 0.46 0.02 1.09 -2.59 0.03 0.63 -1.26
Income Tax Expense		 0.35 0.26 0.39 -0.99 -0.01 0.45 -0.11 0.23 0.08 0.08 0.15
Basic Earnings per Share		 ($0.35) ($0.41) ($0.49) ($0.46) ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76)
Weighted Average Basic Shares Outstanding		 116.56M 116.57M 128.57M 123.08M 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M
Diluted Earnings per Share		 ($0.35) ($0.41) ($0.49) ($0.46) ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76)
Weighted Average Diluted Shares Outstanding		 116.56M 116.57M 128.57M 123.08M 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M
Weighted Average Basic & Diluted Shares Outstanding		 116.58M 129.18M 130.25M 130.41M 130.67M 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M

Annual Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2022 2023 2024
Net Change in Cash & Equivalents		 6.99 94 300 94 -117 259
Net Cash From Operating Activities		 -29 -53 -83 -106 -188 -214
Net Cash From Continuing Operating Activities		 -29 -53 -83 -106 -188 -214
Net Income / (Loss) Continuing Operations		 -29 -66 -107 -157 -211 -259
Consolidated Net Income / (Loss)		 -29 -66 -107 -157 -211 -259
Depreciation Expense		 0.01 0.02 0.07 0.13 0.19 0.23
Amortization Expense		 - - - - 1.13 1.13
Non-Cash Adjustments To Reconcile Net Income		 1.49 8.20 19 35 32 41
Changes in Operating Assets and Liabilities, net		 -1.45 4.81 4.57 15 -11 2.63
Net Cash From Investing Activities		 -0.05 -0.03 -0.21 -0.25 -0.20 -0.36
Net Cash From Continuing Investing Activities		 -0.05 -0.03 -0.21 -0.25 -0.20 -0.36
Purchase of Property, Plant & Equipment		 -0.05 -0.03 -0.21 -0.25 -0.20 -0.36
Net Cash From Financing Activities		 36 147 383 200 71 472
Net Cash From Continuing Financing Activities		 36 147 383 200 71 472
Repurchase of Common Equity		 -0.52 -3.11 -1.24 0.00 -0.27 -6.01
Issuance of Common Equity		 20 0.00 386 200 71 473
Other Financing Activities, net		 16 112 1.10 0.13 0.66 5.69
Effect of Exchange Rate Changes		 - - - -0.09 0.22 0.99
Cash Income Taxes Paid		 0.07 0.06 0.17 - 0.00 0.51

Quarterly Cash Flow Statements for Immunovant

This table details how cash moves in and out of Immunovant's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Net Change in Cash & Equivalents		 -67 -21 27 -56 -47 -60 421 -56 -75 -87 -98
Net Cash From Operating Activities		 -66 -20 -46 -56 -47 -60 -47 -60 -76 -89 -100
Net Cash From Continuing Operating Activities		 -66 -20 -46 -56 -47 -60 -47 -60 -76 -89 -100
Net Income / (Loss) Continuing Operations		 -40 -48 -63 -59 -74 -59 -51 -75 -87 -109 -111
Consolidated Net Income / (Loss)		 -40 -48 -63 -59 -74 -59 -51 -75 -87 -109 -111
Depreciation Expense		 0.04 0.05 0.05 0.05 0.05 0.06 0.06 0.06 0.08 0.09 0.10
Amortization Expense		 - - - - 0.29 0.29 0.30 - 0.07 0.02 0.02
Non-Cash Adjustments To Reconcile Net Income		 7.97 7.88 9.75 6.70 11 11 10 8.89 13 13 12
Changes in Operating Assets and Liabilities, net		 -33 19 7.59 -4.25 16 -12 -6.25 5.63 -2.65 7.67 -1.04
Net Cash From Investing Activities		 -0.04 -0.03 -0.10 -0.03 -0.05 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18
Net Cash From Continuing Investing Activities		 -0.04 -0.03 -0.10 -0.03 -0.05 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18
Purchase of Property, Plant & Equipment		 -0.04 -0.03 -0.10 -0.03 -0.05 -0.03 -0.13 -0.15 -0.18 -0.20 -0.18
Net Cash From Financing Activities		 0.02 - 71 0.23 0.89 0.15 470 1.55 0.69 0.73 2.46
Net Cash From Continuing Financing Activities		 0.02 - 71 0.23 0.89 0.15 470 1.55 0.69 0.73 2.46
Other Financing Activities, net		 0.02 - 0.40 0.23 0.89 0.15 3.11 1.55 0.69 0.73 2.46
Effect of Exchange Rate Changes		 -0.77 -1.22 2.70 -0.49 -0.05 -0.09 -1.61 2.73 0.34 1.05 -0.15

Annual Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2022 2023 2024
Total Assets		 0.41 109 412 516 406 666
Total Current Assets		 0.33 109 409 513 404 666
Cash & Equivalents		 0.33 101 400 494 377 635
Accounts Receivable		 - - 0.60 12 0.70 5.34
Prepaid Expenses		 0.00 5.46 7.72 6.25 27 25
Plant, Property, & Equipment, net		 0.00 0.07 0.20 0.33 0.33 0.46
Total Noncurrent Assets		 0.08 0.25 3.28 2.30 1.17 0.13
Other Noncurrent Operating Assets		 0.08 0.25 3.28 2.30 1.17 0.13
Total Liabilities & Shareholders' Equity		 0.41 109 412 516 406 666
Total Liabilities		 0.38 15 21 46 43 49
Total Current Liabilities		 0.38 15 19 45 43 49
Accounts Payable		 - 4.38 2.43 19 1.35 7.16
Accrued Expenses		 0.08 11 15 25 40 41
Other Current Liabilities		 - 0.00 1.18 1.15 1.52 0.14
Total Noncurrent Liabilities		 0.00 0.00 2.24 1.22 0.05 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 0.02 94 391 470 362 618
Total Preferred & Common Equity		 0.02 94 391 470 362 618
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 94 391 470 362 618
Common Stock		 0.03 185 590 825 928 1,442
Retained Earnings		 -0.00 -91 -199 -355 -566 -826
Accumulated Other Comprehensive Income / (Loss)		 - -0.02 -0.30 0.40 0.85 1.91

Quarterly Balance Sheets for Immunovant

This table presents Immunovant's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Total Assets		 543 459 428 456 351 292 711 590 516 421
Total Current Assets		 540 456 426 454 350 291 711 589 507 413
Cash & Equivalents		 527 427 406 433 330 270 691 560 473 375
Accounts Receivable		 - 13 3.78 0.70 0.82 1.42 1.03 2.42 1.88 2.22
Prepaid Expenses		 13 16 17 21 19 20 19 27 33 36
Plant, Property, & Equipment, net		 0.25 0.33 0.31 0.36 0.33 0.30 0.38 0.57 0.67 0.75
Total Noncurrent Assets		 2.45 2.02 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64
Other Noncurrent Operating Assets		 2.45 2.02 1.74 1.46 0.88 0.59 0.29 0.07 7.66 7.64
Total Liabilities & Shareholders' Equity		 543 459 428 456 351 292 711 590 516 421
Total Liabilities		 38 22 32 42 51 40 32 45 67 68
Total Current Liabilities		 36 21 32 41 51 40 32 45 67 68
Accounts Payable		 3.83 1.07 7.46 14 26 7.51 3.91 11 21 20
Accrued Expenses		 31 19 23 26 24 32 28 34 46 48
Other Current Liabilities		 1.08 1.17 1.19 1.21 0.92 0.61 0.31 0.07 0.05 0.02
Total Noncurrent Liabilities		 1.68 0.92 0.61 0.31 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 505 436 396 415 300 252 679 545 449 353
Total Preferred & Common Equity		 505 436 396 415 300 252 679 545 449 353
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 505 436 396 415 300 252 679 545 449 353
Common Stock		 813 833 841 920 940 950 1,430 1,456 1,469 1,483
Retained Earnings		 -308 -396 -444 -507 -640 -699 -750 -913 -1,022 -1,133
Accumulated Other Comprehensive Income / (Loss)		 0.42 -0.26 -1.24 1.38 0.58 0.51 -0.60 1.82 1.91 2.48

Annual Metrics and Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric 2018 2019 2020 2022 2023 2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -129.77% -64.10% 0.00% -38.62% -30.00%
EBIT Growth		 0.00% -129.76% -64.15% 0.00% -39.36% -29.83%
NOPAT Growth		 0.00% -132.46% -63.62% 0.00% -39.89% -29.52%
Net Income Growth		 0.00% -132.13% -61.82% 0.00% -34.60% -22.93%
EPS Growth		 0.00% -19.38% 20.78% 0.00% -19.58% -9.94%
Operating Cash Flow Growth		 0.00% -86.91% -56.17% 0.00% -77.35% -13.83%
Free Cash Flow Firm Growth		 0.00% 0.00% -84.94% 0.00% 0.00% -19.40%
Invested Capital Growth		 0.00% -1,451,239.29% -33.28% 0.00% 41.49% -25.43%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -23.71% 0.00% 0.00% -6.98%
EBIT Q/Q Growth		 0.00% 0.00% -23.76% 0.00% 0.00% -7.41%
NOPAT Q/Q Growth		 0.00% 0.00% -24.13% 0.00% 0.00% -6.25%
Net Income Q/Q Growth		 0.00% 0.00% -22.75% 0.00% 0.00% -6.53%
EPS Q/Q Growth		 0.00% 0.00% 31.46% 0.00% 0.00% -2.17%
Operating Cash Flow Q/Q Growth		 0.00% -24.21% -56.17% 0.00% -13.81% -1.86%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -51.88%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.07% 100.15% 99.67% 99.95% 100.00% 100.22%
Interest Burden Percent		 100.00% 100.95% 100.00% 100.00% 96.53% 91.21%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -116,483.38% -141.11% -44.25% -33.36% -50.69% -52.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -116,483.38% -141.11% -44.25% -33.36% -50.69% -52.91%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -70.57% -27.44% -33.36% -58.20% -41.98%
Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -109 -153 -198
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -34,806.00% -40.03% -12.68% -9.62% -13.37% -12.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -66 -108 -157 -219 -284
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -29 -66 -108 -157 -217 -282
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 4,072.99 9.34 4.01 1.37 5.57 7.60
Price to Tangible Book Value (P/TBV)		 4,072.99 9.34 4.01 1.37 5.57 7.60
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 12.22 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.07 -1.03 -1.05 -1.05 -1.03
Leverage Ratio		 16.50 1.17 1.07 1.10 1.11 1.09
Compound Leverage Factor		 16.50 1.18 1.07 1.10 1.07 1.00
Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 92.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 7.56% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.02 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -75.33 32.30 44.48 7.53 25.30 55.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 0.85 7.12 21.79 11.52 9.34 13.70
Quick Ratio		 0.85 6.57 21.35 11.37 8.71 13.18
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -40 -74 0.00 -163 -194
Operating Cash Flow to CapEx		 -54,898.08% -172,119.35% -39,679.52% -41,776.38% -95,529.44% -59,507.50%
Free Cash Flow to Firm to Interest Expense		 0.00 -63.60 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -85.37 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -85.42 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -0.00 -6.50 -8.67 -24 -14 -18
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -6.50 -2.16 0.00 9.95 -3.57
Enterprise Value (EV)		 100 778 1,171 148 1,644 4,059
Market Capitalization		 100 879 1,571 641 2,020 4,694
Book Value per Share		 $0.00 $1.67 $4.00 $4.04 $2.78 $4.25
Tangible Book Value per Share		 $0.00 $1.67 $4.00 $4.04 $2.78 $4.25
Total Capital		 0.32 94 391 470 362 618
Total Debt		 0.30 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.03 -101 -400 -494 -377 -635
Capital Expenditures (CapEx)		 0.05 0.03 0.21 0.25 0.20 0.36
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.08 -6.81 -9.91 -25 -15 -18
Debt-free Net Working Capital (DFNWC)		 0.24 94 390 468 361 617
Net Working Capital (NWC)		 -0.06 94 390 468 361 617
Net Nonoperating Expense (NNE)		 8.70 20 32 48 58 61
Net Nonoperating Obligations (NNO)		 -0.03 -101 -400 -494 -377 -635
Total Depreciation and Amortization (D&A)		 0.01 0.02 0.07 0.13 1.32 1.36
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.22) ($1.43) ($1.71) ($1.88)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 97.98M 109.68M 123.08M 138.10M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.22) ($1.43) ($1.71) ($1.88)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 97.98M 109.68M 123.08M 138.10M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.22) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 87.76M 116.51M 130.41M 146.05M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -46 -76 -109 -153 -198
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 -105.07 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -74.01 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -105.12 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -74.06 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.82% -4.68% -1.15% 0.00% -0.13% -2.32%

Quarterly Metrics and Ratios for Immunovant

This table displays calculated financial ratios and metrics derived from Immunovant's official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -29.26% -58.96% 0.00% -94.29% -25.95% 8.56% -30.62% -21.16% -87.21% -92.06%
EBIT Growth		 0.00% -29.38% -58.96% 0.00% -94.93% -26.54% 8.09% -30.61% -20.82% -86.33% -91.14%
NOPAT Growth		 0.00% -31.78% -55.14% 0.00% -94.37% -24.56% 3.86% -25.86% -20.14% -87.29% -85.70%
Net Income Growth		 0.00% -27.12% -52.78% 0.00% -83.13% -22.40% 18.68% -26.73% -17.87% -86.01% -116.12%
EPS Growth		 0.00% -17.14% -36.11% 0.00% -62.86% -9.76% 26.53% -8.70% -5.26% -64.44% -111.11%
Operating Cash Flow Growth		 0.00% 0.00% -45.46% -69.30% 28.03% -197.53% -1.52% -7.00% -60.86% -47.60% -113.15%
Free Cash Flow Firm Growth		 0.00% 49.49% -228.09% 0.00% 0.00% -42.35% -1.40% 0.00% -419.24% -113.97% -40.69%
Invested Capital Growth		 0.00% 0.00% 17.96% 0.00% -424.02% -80.72% 35.34% -25.43% 49.01% -31.85% -90.36%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -22.01% -34.77% 2.87% -21.65% 20.91% 2.16% -38.08% -12.84% -22.20% -0.38%
EBIT Q/Q Growth		 0.00% -21.99% -34.75% 2.86% -22.08% 20.81% 2.14% -38.05% -12.93% -22.13% -0.39%
NOPAT Q/Q Growth		 0.00% -22.88% -29.05% -0.36% -22.12% 21.25% 0.40% -31.40% -16.57% -22.76% 1.25%
Net Income Q/Q Growth		 0.00% -18.71% -31.92% 6.00% -24.41% 20.66% 12.35% -46.48% -15.71% -25.21% -1.84%
EPS Q/Q Growth		 0.00% -17.14% -19.51% 6.12% -23.91% 21.05% 20.00% -38.89% -20.00% -23.33% -2.70%
Operating Cash Flow Q/Q Growth		 -99.72% 69.33% -129.84% -20.26% 15.10% -26.79% 21.58% -26.75% -27.64% -16.34% -13.25%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -97.31% 100.00% 0.00% -126.15% -40.54% -7.33% -52.22% 6.81% 7.59%
Invested Capital Q/Q Growth		 0.00% -207.94% -78.85% 21.71% -114.38% 39.80% 36.01% -51.88% 12.85% -55.67% 7.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.88% 100.55% 100.62% 98.36% 99.99% 100.78% 99.79% 100.31% 100.09% 100.07% 100.14%
Interest Burden Percent		 100.00% 97.64% 95.52% 94.55% 94.79% 94.22% 85.22% 89.96% 92.38% 94.72% 96.03%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% 0.00% 0.00% -50.69% -66.41% -78.84% -44.51% -52.91% -64.54% -92.17% -74.17%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 0.00% 0.00% -50.69% -66.41% -78.84% -44.51% -52.91% -64.54% -92.17% -74.17%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% 0.00% 0.00% -81.54% -101.37% -35.84% 0.00% -50.04% -71.93% -108.53%
Net Operating Profit after Tax (NOPAT)		 -28 -35 -45 -45 -55 -43 -43 -57 -66 -81 -80
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.83% -6.51% -3.84% -3.84% -5.02% -4.56% -1.48% -3.70% -4.75% -7.57% -5.84%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -6.34% - - - -22.69%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -40 -49 -66 -64 -78 -62 -60 -83 -94 -115 -116
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -40 -49 -66 -64 -78 -61 -60 -83 -94 -115 -115
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.04 1.64 5.53 5.57 8.25 19.92 8.97 7.60 7.08 9.29 10.31
Price to Tangible Book Value (P/TBV)		 1.04 1.64 5.53 5.57 8.25 19.92 8.97 7.60 7.08 9.29 10.31
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -1.03 -1.04 -1.04 -1.03 -1.04 -1.03 -1.03 -1.05 -1.06 -1.03
Leverage Ratio		 1.05 1.08 1.09 1.11 1.10 1.11 1.07 1.09 1.11 1.15 1.10
Compound Leverage Factor		 1.05 1.06 1.04 1.05 1.04 1.05 0.91 0.98 1.03 1.09 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 26.56 26.64 71.75 113.30 56.91 49.80 35.08 28.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 21.48 13.41 11.01 9.34 6.82 7.23 22.14 13.70 13.08 7.61 6.04
Quick Ratio		 20.73 12.89 10.50 8.71 6.44 6.74 21.56 13.18 12.49 7.12 5.52
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -25 -49 0.00 -16 -35 -49 -53 -81 -75 -70
Operating Cash Flow to CapEx		 -156,711.90% -65,116.13% -47,341.84% -214,588.46% -105,266.67% -176,647.06% -35,952.67% -39,799.33% -41,867.58% -45,228.06% -55,772.78%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.29 -10 -18 -14 -30 -18 -12 -18 -15 -24 -22
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -10 3.93 0.00 -39 -8.09 6.34 -3.57 15 -5.77 -10
Enterprise Value (EV)		 27 245 1,860 1,644 2,144 4,747 5,404 4,059 3,296 3,700 3,261
Market Capitalization		 454 651 2,293 2,020 2,474 5,016 6,095 4,694 3,856 4,173 3,636
Book Value per Share		 $3.75 $3.39 $3.21 $2.78 $2.30 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40
Tangible Book Value per Share		 $3.75 $3.39 $3.21 $2.78 $2.30 $1.93 $4.70 $4.25 $3.73 $3.07 $2.40
Total Capital		 436 396 415 362 300 252 679 618 545 449 353
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -427 -406 -433 -377 -330 -270 -691 -635 -560 -473 -375
Capital Expenditures (CapEx)		 0.04 0.03 0.10 0.03 0.05 0.03 0.13 0.15 0.18 0.20 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 7.86 -11 -19 -15 -31 -19 -12 -18 -16 -32 -30
Debt-free Net Working Capital (DFNWC)		 435 394 413 361 299 251 679 617 544 441 344
Net Working Capital (NWC)		 435 394 413 361 299 251 679 617 544 441 344
Net Nonoperating Expense (NNE)		 12 13 18 14 19 15 8.33 19 21 28 31
Net Nonoperating Obligations (NNO)		 -427 -406 -433 -377 -330 -270 -691 -635 -560 -473 -375
Total Depreciation and Amortization (D&A)		 0.04 0.05 0.05 0.05 0.34 0.35 0.35 0.06 0.15 0.11 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) ($0.41) ($0.49) ($0.46) ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76)
Adjusted Weighted Average Basic Shares Outstanding		 116.56M 116.57M 128.57M 123.08M 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M
Adjusted Diluted Earnings per Share		 ($0.35) ($0.41) ($0.49) ($0.46) ($0.57) ($0.45) ($0.36) ($0.50) ($0.60) ($0.74) ($0.76)
Adjusted Weighted Average Diluted Shares Outstanding		 116.56M 116.57M 128.57M 123.08M 130.50M 131.16M 144.52M 138.10M 146.09M 146.47M 146.92M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 116.58M 129.18M 130.25M 130.41M 130.67M 144.66M 145.29M 146.05M 146.37M 146.78M 169.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -28 -35 -45 -45 -55 -43 -43 -57 -66 -81 -80
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -0.13% 0.00% 0.00% -2.47% -2.32% 0.00% 0.00% 0.00%

Frequently Asked Questions About Immunovant's Financials

When does Immunovant's fiscal year end?

According to the most recent income statement we have on file, Immunovant's financial year ends in March. Their financial year 2024 ended on March 31, 2024.

How has Immunovant's net income changed over the last 5 years?

Immunovant's net income appears to be on an upward trend, with a most recent value of -$259.34 million in 2024, rising from -$28.60 million in 2018. The previous period was -$210.96 million in 2023.

What is Immunovant's operating income?
Immunovant's total operating income in 2024 was -$282.71 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $282.71 million
How has Immunovant revenue changed over the last 5 years?

Over the last 5 years, Immunovant's total revenue changed from $0.00 in 2018 to $0.00 in 2024, a change of 0.0%.

How much debt does Immunovant have?

Immunovant's total liabilities were at $48.61 million at the end of 2024, a 12.1% increase from 2023, and a 12,676.5% increase since 2018.

How much cash does Immunovant have?

In the past 5 years, Immunovant's cash and equivalents has ranged from $325 thousand in 2018 to $635.37 million in 2024, and is currently $635.37 million as of their latest financial filing in 2024.

How has Immunovant's book value per share changed over the last 5 years?

Over the last 5 years, Immunovant's book value per share changed from 0.00 in 2018 to 4.25 in 2024, a change of 386,427.3%.


Related Companies

This page (NASDAQ:IMVT) was last updated on 4/24/2025 by MarketBeat.com Staff
From Our Partners
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
James Altucher: Do not invest in AI unless…
I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...
Paradigm Press | Sponsored
The Exact July Date the AI Correction Will End?
AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...
Brownstone Research | Sponsored
This Is The Moment You Betray Trump (Or Prove Them Wrong)
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored
Trump’s treachery
Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...
Porter & Company | Sponsored
Two Unmistakable Patterns Return…
The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...
Golden Portfolio | Sponsored